GDRX · GoodRx Holdings, Inc.
Price & Indicators
Up next
AI Brief
TL;DR.
AI-generated from the earnings call and 8-K · may contain errors · not investment advice
Ask ALVIS about this →Equibles Rating
blended score · not investment adviceBlended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Guidance & track record
Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.
Technicals
trend & momentum for long-term holders NeutralIllustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
the company's own KPIs, from its earnings releases, calls, and filings| Metric | Latest | Period | YoY |
|---|---|---|---|
| Adjusted EBITDA non-GAAP | $58.3M | Q1 2026 | — |
| Adjusted Net Income Margin non-GAAP | 11.9% | Q1 2026 | — |
| Subscription plans | 674K | As of December 31, 2025 | — |
Figures exactly as the company stated them · click a metric with a to chart its history · period links open the stating document · "call" marks figures stated on the earnings call, "filing" figures stated in the 10-K/10-Q · YoY needs the prior-year figure on file
Versus peers
Health Information Services — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
GDRX
this stock
GoodRx Holdings, Inc.
|
$1.00B | +5.9% | +0.6% | 49.3 | 1.9% |
|
VEEV
Veeva Systems Inc
|
$30.25B | -19.6% | +28.1% | 33.0 | 4.9% |
|
PMDIY
Pro Medicus Ltd./ADR
|
$15.41B | -10.9% | — | — | 0.0% |
|
BTSG
BrightSpring Health Services, Inc.
|
$14.14B | +94.7% | -0.4% | 52.1 | 5.1% |
|
HQY
Healthequity, Inc.
|
$7.91B | +3.0% | +28.7% | 35.4 | 6.0% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionPerformance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| GDRX | -8.0% | +4.0% | +19.6% | -0.4% | +5.9% |
| SPY | -1.7% | +0.7% | +6.4% | -1.2% | +8.3% |
| vs SPY | -6.3% | +3.3% | +13.2% | +0.8% | -2.4% |
Capital returns
Dividends per share over the trailing 365 days by ex-date · buyback figures as last reported in SEC filings ("spent" derived as authorized − remaining; when several programs run concurrently, authorized is their combined total per the newest filing) · components shown separately — trailing-year buyback spend isn't tracked, so no combined shareholder yield is derived.